Medical News

Moreover Technologies - Pharma industry news - 30 of 24863 retur...
Moreover Technologies - Real-time news and blogs from thousands of sources

Beware Teeth Whitening Scams! - Sponsored Link
Ad - Discover A Mum's Secret Trick That Gave Her A Celebrity Smile For 3.35!
Strides in talks for Ascent Pharma stake
NEW DELHI: Drug maker Strides Arcolab on Tuesday said it is in talks with Ascent Pharmahealth, listed on the Australian Stock Exchange, for acquiring a minority stake in the company. Bangalore-based Strides Arcolab already holds 57 per cent stake in
Strides proposes to acquire minority stake in Ascent Pharma
NEW DELHI: Drug maker Strides Arcolab on Tuesday said it is in talks with Ascent Pharmahealth, listed on the Australian Stock Exchange, for acquiring a minority stake in the company. Bangalore-based Strides Arcolab already holds 57 per cent stake in
Breast cancer drug Taxotere PBS listed
A chemotherapy drug for women with early stage breast cancer has been approved for PBS listing, making Australia the first country in the world to provide a nationwide subsidy for the therapy. Treatment with Taxotere (docetaxel) in combination with
URL Pharma Expands Colcrys(R) Patient Assistance Program
URL Pharma, Inc. today announced the launch of an expanded Colcrys® (colchicine, USP) Patient Assistance Program (PAP) that significantly increases the number of patients eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with
URL Pharma Expands Colcrys(R) Patient Assistance Program
URL Pharma, Inc. today announced the launch of an expanded Colcrys® (colchicine, USP) Patient Assistance Program (PAP) that significantly increases the number of patients eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with
URL Pharma Expands Colcrys(R) Patient Assistance Program
URL Pharma, Inc. today announced the launch of an expanded Colcrys® (colchicine, USP) Patient Assistance Program (PAP) that significantly increases the number of patients eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with
Acrux signs Axiron deal with Eli Lilly
Extract not available.
Trubion Pharmaceuticals, Inc. Reports Fourth-Quarter and Year-Ended 2009 Fina...
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced financial results for its fourth quarter and year ended Dec. 31, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Fourth-Quarter and Year-Ended 2009 Financial Results
Strides in talks to up stake in Ascent Pharma
Strides Arcolab Ltd said on Tuesday it is in discussions with Australia-based Ascent Pharmahealth Ltd to buy a further stake in the unit. The proposal includes a cash offer of A$0.35 per Ascent share, Strides, which already owns 57 percent in Ascent
Savient Pharmaceuticals resubmits KRYSTEXXA BLA
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA? (pegloticase) as a treatment for chronic gout in patients
Cadence Pharmaceuticals reports 4Q loss
SAN DIEGO -- Cadence Pharmaceuticals Inc. on Monday reported a fourth quarter loss on higher expenses related to a pain and fever drug that has yet to receive government approval. In the fourth quarter, the biopharmaceutical company lost $15.3 million,
Medivir Inks Licensing Pact with Daewoong Pharmaceutical
(Close-Up Media via COMTEX News Network) -- Medivir AB (Sweden) has announced a license agreement with Daewoong Pharmaceutical Co. (South Korea) for its hepatitis B virus (HBV) polymerase inhibitor drug, lagociclovir valactate (MIV-210). Under the terms
URL Pharma Expands Colcrys(R) Patient Assistance Program
URL Pharma, Inc. today announced the launch of an expanded Colcrys® (colchicine, USP) Patient Assistance Program (PAP) that significantly increases the number of patients eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with
URL Pharma Expands Colcrys(R) Patient Assistance Program
URL Pharma, Inc. today announced the launch of an expanded Colcrys® (colchicine, USP) Patient Assistance Program (PAP) that significantly increases the number of patients eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with